Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
T. Ciuleanu
No relevant relationships to disclose
V. Nikolic
No relevant relationships to disclose
E. Shmueli
No relevant relationships to disclose
D. Vrbanec
No relevant relationships to disclose
S. Plate
No relevant relationships to disclose
Z. M. Krmpotic
No relevant relationships to disclose
M. Dank
No relevant relationships to disclose
G. Purkalne
No relevant relationships to disclose
T. Brodowicz
No relevant relationships to disclose
C. Zielinski
Consultant or Advisory Role - Merck Serono; Roche